Valuation: Verastem, Inc.

Market Cap 51Cr 44Cr 41Cr 38Cr 72Cr 4.86TCr 73Cr 487.3Cr 190.49Cr 2.43TCr 191.73Cr 187.52Cr 8.04TCr P/E 2026 *
-3.67x
P/E 2027 * -5.18x
Enterprise Value 35Cr 30Cr 28Cr 26Cr 49Cr 3.29TCr 49Cr 329.81Cr 128.93Cr 1.64TCr 129.76Cr 126.92Cr 5.44TCr EV / Sales 2026 *
3.39x
EV / Sales 2027 * 1.69x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+2.11%
1 week-6.74%
Current month+0.17%
1 month+29.11%
3 months-2.35%
6 months-14.43%
Current year-24.74%
1 week 5.54
Extreme 5.54
6.16
1 month 4.3
Extreme 4.3
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/05/26 Free

Chairman

36,000 0.0410%
21/05/26 Free

Director

36,000 0.0410%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+2.11%-6.74%-3.33%-47.94% 51Cr
+10.00%+14.90%+53.89%+87.07% 6.25TCr
+0.80%-5.70%+23.89%+62.65% 5.24TCr
-0.98%-1.19%-16.98%-14.21% 2.31TCr
+0.30%-5.17%-11.23%+349.07% 2.14TCr
+1.73%-1.57%+32.81%-25.80% 1.78TCr
+4.29%+8.97%+200.03%+341.85% 1.55TCr
+2.91%-0.52%+14.32%+617.39% 1.47TCr
+1.71%-0.90%+52.13%+176.27% 1.41TCr
+4.16%+4.44%+444.12%+183.06% 1.26TCr
Average +2.69%+0.22%+78.97%+172.94% 2.35TCr
Weighted average by Cap. +3.69%+1.81%+60.59%+147.21%

Financials

2026 *2027 *
Net sales 10Cr 8.85Cr 8.25Cr 7.58Cr 14Cr 969.03Cr 14Cr 97Cr 38Cr 484.4Cr 38Cr 37Cr 1.61TCr 18Cr 15Cr 14Cr 13Cr 25Cr 1.7TCr 25Cr 170.23Cr 67Cr 848.05Cr 67Cr 66Cr 2.81TCr
Net income -17Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -24Cr -157.99Cr -62Cr -787.07Cr -62Cr -61Cr -2.61TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.35TCr -20Cr -135.6Cr -53Cr -675.52Cr -53Cr -52Cr -2.24TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -23Cr -157.49Cr -62Cr -784.58Cr -62Cr -61Cr -2.6TCr -21Cr -18Cr -17Cr -16Cr -29Cr -1.99TCr -30Cr -200.06Cr -78Cr -996.65Cr -79Cr -77Cr -3.3TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
04/26/04 $5.810 +2.11% 17,91,796
03/26/03 $5.690 -1.90% 12,88,075
31/26/31 $5.800 -4.92% 18,57,262
30/26/30 $6.100 +1.50% 14,51,955
29/26/29 $6.010 -3.53% 22,49,888
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.810USD
Average target price
15.00USD
Spread / Average Target
+158.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock